Antharis Therapeutics, Inc.
PrivateLast Round
Series A
Jul 14, 2022
Total Funding Raised
$48.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antharis Therapeutics, Inc. is a biotechnology company that develops monoclonal antibodies and antibody-drug conjugates to treat cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antharis Therapeutics, Inc. Comparables
Compare Antharis Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abalone Bio | 80% | |
| Elemental Biologics | 79% | |
| Catena Biosciences | 79% | |
Antharis Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 14, 2022 | ||||
| Seed | Dec 1, 2020 |
Antharis Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yazbeck & Co. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 636% MoM.
- Jun 26, 2026
Grew 25% QoQ, from 16 to 20 employees.
Antharis Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Antharis Therapeutics, Inc.'s valuation, stock price, and market status.